Valvular & structural heart disease
Predictors and 5-Year Clinical Outcomes of Pacemaker After Transcatheter Aortic Valve Replacement (TAVR): Analysis From the PARTNER 2 SAPIEN 3 Registries
Authors' conclusion
PPM was required in 12.5% of patients without prior PPM who underwent TAVR with a SAPIEN 3 valve in the PARTNER 2 S3 registries and was not associated with worse clinical outcomes, including mortality, at 5 years.
Study context
- Population
- Intermediate and high surgical risk patients without prior permanent pacemaker (PPM) undergoing TAVR with the SAPIEN 3 transcatheter heart valve (THV)
- Participants
- 857 participants
- Comparison
- New PPM vs no new PPM after TAVR
- New PPMn = 107
- Primary endpoint
- New PPM within 30 days after TAVR
- Follow-up
- 30 days
Primary result
As reported in the abstract
New PPM
12.5%
107
Further findings
| Outcome | Adj HR (95% CI) | P value | |
|---|---|---|---|
| All-cause mortality · 5 years (median follow-up 1,682.0 days [min 2.0, max 2,283.0]) | 1.20 (0.85–1.70) | P = 0.30 | |
| Repeat hospitalization · 5 years | 1.22 (0.67–2.21) | P = 0.52 | |
| 0.512Adj HR (log scale) |
| Outcome | New PPM | No new PPM | P value |
|---|---|---|---|
| LVEF (decline at 1 year persisting) · 5 years | 55.1 ± 2.55 | 60.4 ± 0.65 | P = 0.02 |
Original publication
Predictors and 5-Year Clinical Outcomes of Pacemaker After TAVR: Analysis From the PARTNER 2 SAPIEN 3 Registries. JACC Cardiovasc Interv. Published 10 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →